ID: ALA408706

Max Phase: Preclinical

Molecular Formula: C21H32O3

Molecular Weight: 332.48

Molecule Type: Small molecule

Representations

Canonical SMILES:  CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@@]21C

Standard InChI:  InChI=1S/C21H32O3/c1-13(22)21(24)11-8-18-16-5-4-14-12-15(23)6-9-19(14,2)17(16)7-10-20(18,21)3/h4,15-18,23-24H,5-12H2,1-3H3/t15-,16+,17-,18-,19-,20-,21-/m0/s1

Standard InChI Key:  JERGUCIJOXJXHF-TVWVXWENSA-N

Molecule Features

Natural Product: Yes

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 332.48

Molecular Weight (Monoisotopic): 332.2351

AlogP: 3.63

#Rotatable Bonds: 1

Polar Surface Area: 57.53

Molecular Species: NEUTRAL

HBA: 3

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 3

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 12.70

CX Basic pKa:

CX LogP: 2.83

CX LogD: 2.83

Aromatic Rings: 0

Heavy Atoms: 24

QED Weighted: 0.72

Np Likeness Score: 2.31

References

1. Silverman BD, Platt DE..  (1996)  Comparative molecular moment analysis (CoMMA): 3D-QSAR without molecular superposition.,  39  (11): [PMID:8667357] [10.1021/jm950589q]

2. Jain AN, Koile K, Chapman D..  (1994)  Compass: predicting biological activities from molecular surface properties. Performance comparisons on a steroid benchmark.,  37  (15): [PMID:8057280] [10.1021/jm00041a010]

3. Good AC, Peterson SJ, Richards WG..  (1993)  QSAR's from similarity matrices. Technique validation and application in the comparison of different similarity evaluation methods.,  36  (20): [PMID:8411009] [10.1021/jm00072a012]

4. Crippen GM..  (1997)  Validation of EGSITE2, a mixed integer program for deducing objective site models for experimental binding data.,  40  (20): [PMID:9379435] [10.1021/jm970211n]

5. So SS, Karplus M..  (1997)  Three-dimensional quantitative structure-activity relationships from molecular similarity matrices and genetic neural networks. 1. Method and validations.,  40  (26): [PMID:9435904] [10.1021/jm970487v]

6. Good AC, So SS, Richards WG..  (1993)  Structure-activity relationships from molecular similarity matrices.,  36  (4): [PMID:8474098] [10.1021/jm00056a002]

7. Cherkasov A, Ban F, Santos-Filho O, Thorsteinson N, Fallahi M, Hammond GL..  (2008)  An updated steroid benchmark set and its application in the discovery of novel nanomolar ligands of sex hormone-binding globulin.,  51  (7): [PMID:18330978] [10.1021/jm7011485]

8. Bellavance E, Luu-The V, Poirier D..  (2009)  Potent and selective steroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 7, an enzyme that catalyzes the reduction of the key hormones estrone and dihydrotestosterone.,  52  (23): [PMID:19772289] [10.1021/jm900921c]

9. PubChem BioAssay data set, 

10. Tukey RH, Strassburg CP..  (2000)  Human UDP-glucuronosyltransferases: metabolism, expression, and disease.,  40  (1): [PMID:10836148] [10.1146/annurev.pharmtox.40.1.581]

Source

Source(2):

• Scientific Literature
• PubChem BioAssays